EGFR and non-small cell lung carcinoma: Testing for EGFR mutation was the most common molecular test in all countries, and the overall percentages of positive tests for EGFR mutation in nonsquamous NSCLC were 17–28% in the non-Asian countries and 42–67% in the Asian countries.